Yaodong Ding
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yaodong Ding has a total of 48 co-authors. Here are the top co-authors by number of shared publications:
- Yong Zeng
Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University
7 shared publications Ruixiang Feng
Department of Cardiology, Center for Coronary Artery Disease, Beijing Anzhen Hospital, Capital Medical University, 100029 Beijing, China
4 shared publicationsJiayi Han
Department of Cardiology, Center for Coronary Artery Disease, Beijing Anzhen Hospital, Capital Medical University, 100029 Beijing, China
3 shared publicationsTengxiao Zhao
Department of Cardiology, Center for Coronary Artery Disease, Beijing Anzhen Hospital, Capital Medical University, 100029 Beijing, China
3 shared publicationsWenjie Wang
Department of Cardiology, Center for Coronary Artery Disease, Beijing Anzhen Hospital, Capital Medical University, 100029 Beijing, China
3 shared publicationsZehao Zhao
Department of Cardiology, Center for Coronary Artery Disease, Beijing Anzhen Hospital, Capital Medical University, 100029 Beijing, China
3 shared publications
Latest Publications
- Open Access
- 1 October 2026
- Published by Wiley in Advanced Science
A Facial Foundation Model for Clinical Biomarker Prediction and Real‐World Mobile Deployment
While most biomarkers currently rely on invasive laboratory testing, which limits large‐scale or repeated screening, scalable non‐invasive methods could transform population screening and personalized health management. Facial photographs, as a ubiquitous and non‐invasive data source, offer such potential but remain underexplored for clinical biomarker prediction. Existing supervised approaches are constrained by the availability of clinically labeled data, whereas general‐purpose vision models are optimized for non‐clinical tasks and may inadequately capture subtle, multiscale, and spatially distributed clinical facial features. To address these limitations, we developed MedicalFaceFound, a facial foundation model pretrained on over 10 million images and evaluated across 62 biomarkers spanning eight physiological systems. It performed best among the Swin‐Large and ResNet18 for 45 (73%) biomarkers and generalized across four independent external cohorts (median Pearson's r = 0.172), with strong performance for RBC, eGFR, and HDL‐C (median r = 0.478, 0.442, and 0.430, respectively). MedicalFaceFound also outperformed polygenic risk score models for 14 of 26 biomarkers, and face‐estimated cardiovascular biomarkers were strongly associated with coronary stenosis (AUC = 0.66). The model retained predictive performance with 400 labeled samples and was feasible to deploy as a smartphone application, supporting scalable, non‐invasive biomarker assessment and personalized risk screening.
- 1 October 2026
- Published by Wiley in Advanced Science
Open AccessA Facial Foundation Model for Clinical Biomarker Prediction and Real‐World Mobile Deployment
While most biomarkers currently rely on invasive laboratory testing, which limits large‐scale or repeated screening, scalable non‐invasive methods could transform population screening and personalized health management. Facial photographs, as a ubiquitous and non‐invasive data source, offer such potential but remain underexplored for clinical biomarker prediction. Existing supervised approaches are constrained by the availability of clinically labeled data, whereas general‐purpose vision models are optimized for non‐clinical tasks and may inadequately capture subtle, multiscale, and spatially distributed clinical facial features. To address these limitations, we developed MedicalFaceFound, a facial foundation model pretrained on over 10 million images and evaluated across 62 biomarkers spanning eight physiological systems. It performed best among the Swin‐Large and ResNet18 for 45 (73%) biomarkers and generalized across four independent external cohorts (median Pearson's r = 0.172), with strong performance for RBC, eGFR, and HDL‐C (median r = 0.478, 0.442, and 0.430, respectively). MedicalFaceFound also outperformed polygenic risk score models for 14 of 26 biomarkers, and face‐estimated cardiovascular biomarkers were strongly associated with coronary stenosis (AUC = 0.66). The model retained predictive performance with 400 labeled samples and was feasible to deploy as a smartphone application, supporting scalable, non‐invasive biomarker assessment and personalized risk screening.
- Open Access
- 21 May 2026
- Published by IMR Press in Reviews in Cardiovascular Medicine
- Vol. 27 (5)
Identification and Validation of an Explainable Predictive Model For Heart Failure in Patients With Hypertension
Background: Heart failure (HF) is a heterogeneous syndrome affecting over 60 million individuals globally. Patients with hypertension are particularly susceptible to developing HF. Therefore, timely identification and predictive assessment of HF risk have significant clinical implications in this population. Thus, this study aimed to develop a new interpretable machine learning (ML) model for HF prediction. Methods: Using data from the Systolic Blood Pressure Intervention Trial (SPRINT), a random under-sampling technique was applied to address class imbalance in the target variable, achieving a 1:1 ratio between positive and negative samples. By randomly matching 162 individuals without HF events to those with events, a balanced dataset comprising 324 participants was constructed. The test set comprised 40% of the total dataset to ensure a robust evaluation of model performance. Seven ML algorithms, including support vector machine (SVM), adaptive boosting (Adaboost), naïve Bayes (NB), logistic regression (LR), gradient boosting machine (GBM), random forest (RF), and multilayer perceptron (MLP), were employed to construct the predictive models. Model performance was evaluated using the area under the curve (AUC), decision curve analysis (DCA), calibration curves, and other metrics. The SHapley Additive exPlanations (SHAP) approach was employed to rank feature significance and provide interpretability for the final model. Results: Over a median follow-up of 3.88years, 162 patients (1.8%) developed incident HF. Among the seven ML models, GBM demonstrated the best performance. A total of 14 features were retained after the least absolute shrinkage and selection operator (LASSO) selection. The final model exhibited robust predictive capability for identifying HF risk, with an overall accuracy of 0.731, a precision of 0.770, and an AUC (95% confidence interval (CI)) of 0.763 (0.676–0.840). Conclusion: The GBM-based explainable prediction model demonstrated robust performance in predicting HF risk among patients with hypertension.
- 21 May 2026
- Published by IMR Press in Reviews in Cardiovascular Medicine
- Vol. 27 (5)
Open AccessIdentification and Validation of an Explainable Predictive Model For Heart Failure in Patients With Hypertension
Background: Heart failure (HF) is a heterogeneous syndrome affecting over 60 million individuals globally. Patients with hypertension are particularly susceptible to developing HF. Therefore, timely identification and predictive assessment of HF risk have significant clinical implications in this population. Thus, this study aimed to develop a new interpretable machine learning (ML) model for HF prediction. Methods: Using data from the Systolic Blood Pressure Intervention Trial (SPRINT), a random under-sampling technique was applied to address class imbalance in the target variable, achieving a 1:1 ratio between positive and negative samples. By randomly matching 162 individuals without HF events to those with events, a balanced dataset comprising 324 participants was constructed. The test set comprised 40% of the total dataset to ensure a robust evaluation of model performance. Seven ML algorithms, including support vector machine (SVM), adaptive boosting (Adaboost), naïve Bayes (NB), logistic regression (LR), gradient boosting machine (GBM), random forest (RF), and multilayer perceptron (MLP), were employed to construct the predictive models. Model performance was evaluated using the area under the curve (AUC), decision curve analysis (DCA), calibration curves, and other metrics. The SHapley Additive exPlanations (SHAP) approach was employed to rank feature significance and provide interpretability for the final model. Results: Over a median follow-up of 3.88years, 162 patients (1.8%) developed incident HF. Among the seven ML models, GBM demonstrated the best performance. A total of 14 features were retained after the least absolute shrinkage and selection operator (LASSO) selection. The final model exhibited robust predictive capability for identifying HF risk, with an overall accuracy of 0.731, a precision of 0.770, and an AUC (95% confidence interval (CI)) of 0.763 (0.676–0.840). Conclusion: The GBM-based explainable prediction model demonstrated robust performance in predicting HF risk among patients with hypertension.
- Open Access
- 21 May 2026
- Vol. 27 (5)
Identification and Validation of an Explainable Predictive Model For Heart Failure in Patients With Hypertension
Heart failure (HF) is a heterogeneous syndrome affecting over 60 million individuals globally. Patients with hypertension are particularly susceptible to developing HF. Therefore, timely identification and predictive assessment of HF risk have significant clinical implications in this population. Thus, this study aimed to develop a new interpretable machine learning (ML) model for HF prediction. Using data from the Systolic Blood Pressure Intervention Trial (SPRINT), a random under-sampling technique was applied to address class imbalance in the target variable, achieving a 1:1 ratio between positive and negative samples. By randomly matching 162 individuals without HF events to those with events, a balanced dataset comprising 324 participants was constructed. The test set comprised 40% of the total dataset to ensure a robust evaluation of model performance. Seven ML algorithms, including support vector machine (SVM), adaptive boosting (Adaboost), naïve Bayes (NB), logistic regression (LR), gradient boosting machine (GBM), random forest (RF), and multilayer perceptron (MLP), were employed to construct the predictive models. Model performance was evaluated using the area under the curve (AUC), decision curve analysis (DCA), calibration curves, and other metrics. The SHapley Additive exPlanations (SHAP) approach was employed to rank feature significance and provide interpretability for the final model. Over a median follow-up of 3.88years, 162 patients (1.8%) developed incident HF. Among the seven ML models, GBM demonstrated the best performance. A total of 14 features were retained after the least absolute shrinkage and selection operator (LASSO) selection. The final model exhibited robust predictive capability for identifying HF risk, with an overall accuracy of 0.731, a precision of 0.770, and an AUC (95% confidence interval (CI)) of 0.763 (0.676–0.840). The GBM-based explainable prediction model demonstrated robust performance in predicting HF risk among patients with hypertension.
- 21 May 2026
- Vol. 27 (5)
Open AccessIdentification and Validation of an Explainable Predictive Model For Heart Failure in Patients With Hypertension
Heart failure (HF) is a heterogeneous syndrome affecting over 60 million individuals globally. Patients with hypertension are particularly susceptible to developing HF. Therefore, timely identification and predictive assessment of HF risk have significant clinical implications in this population. Thus, this study aimed to develop a new interpretable machine learning (ML) model for HF prediction. Using data from the Systolic Blood Pressure Intervention Trial (SPRINT), a random under-sampling technique was applied to address class imbalance in the target variable, achieving a 1:1 ratio between positive and negative samples. By randomly matching 162 individuals without HF events to those with events, a balanced dataset comprising 324 participants was constructed. The test set comprised 40% of the total dataset to ensure a robust evaluation of model performance. Seven ML algorithms, including support vector machine (SVM), adaptive boosting (Adaboost), naïve Bayes (NB), logistic regression (LR), gradient boosting machine (GBM), random forest (RF), and multilayer perceptron (MLP), were employed to construct the predictive models. Model performance was evaluated using the area under the curve (AUC), decision curve analysis (DCA), calibration curves, and other metrics. The SHapley Additive exPlanations (SHAP) approach was employed to rank feature significance and provide interpretability for the final model. Over a median follow-up of 3.88years, 162 patients (1.8%) developed incident HF. Among the seven ML models, GBM demonstrated the best performance. A total of 14 features were retained after the least absolute shrinkage and selection operator (LASSO) selection. The final model exhibited robust predictive capability for identifying HF risk, with an overall accuracy of 0.731, a precision of 0.770, and an AUC (95% confidence interval (CI)) of 0.763 (0.676–0.840). The GBM-based explainable prediction model demonstrated robust performance in predicting HF risk among patients with hypertension.
- Open Access
- 8 May 2026
- Published by Termedia Sp. z.o.o. in Archives of Medical Science
- Vol. 22 (3) , 1359-1371
Cognitive screening for cardiovascular risk stratification in stable coronary artery disease: a prospective cohort study
Introduction: While cognitive impairment is prevalent in patients with coronary artery disease (CAD), its prognostic significance in stable CAD patients remains unclear. Material and methods: In this prospective cohort study of 6,130 stable CAD patients, baseline cognitive function was assessed using Montreal Cognitive Assessment (MoCA). The primary outcome was major adverse cardiovascular events (MACE), including all-cause death, nonfatal myocardial infarction, and nonfatal stroke. Unplanned revascularization was specified as a secondary outcome. Kaplan-Meier survival analysis and Cox regression were used to assess the prognostic impact of cognitive impairment. The robustness of the findings was tested via subgroup analyses and sensitivity analyses. Results: Over a median follow-up of 549 days, 123 (2.0%) patients experienced a MACE, and 315 (5.1%) underwent unplanned revascularization. Patients in the MACE group had significantly lower baseline cognitive function. Worse cognitive function was observed in older adults, females, individuals with lower educational attainment, and those with cardiometabolic risk factors. Patients with cognitive impairment had a significantly higher incidence of MACE (log-rank p = 0.001). In contrast, no significant difference was observed in the incidence of unplanned revascularization (log-rank p = 0.791). After multivariable adjustment, cognitive impairment remained an independent predictor of MACE (HR = 1.58, 95% CI: 1.06–2.37, p = 0.026). Sensitivity analyses confirmed the robustness of primary findings. In subgroup analyses, cognitive impairment showed a consistent trend toward increased MACE risk across all strata, with the notable exception of the subgroup with low-density lipoprotein cholesterol < 1.8 mmol/l. Conclusions: Baseline cognitive impairment is an independent predictor of MACE in stable CAD patients.
- 8 May 2026
- Published by Termedia Sp. z.o.o. in Archives of Medical Science
- Vol. 22 (3) , 1359-1371
Open AccessCognitive screening for cardiovascular risk stratification in stable coronary artery disease: a prospective cohort study
Introduction: While cognitive impairment is prevalent in patients with coronary artery disease (CAD), its prognostic significance in stable CAD patients remains unclear. Material and methods: In this prospective cohort study of 6,130 stable CAD patients, baseline cognitive function was assessed using Montreal Cognitive Assessment (MoCA). The primary outcome was major adverse cardiovascular events (MACE), including all-cause death, nonfatal myocardial infarction, and nonfatal stroke. Unplanned revascularization was specified as a secondary outcome. Kaplan-Meier survival analysis and Cox regression were used to assess the prognostic impact of cognitive impairment. The robustness of the findings was tested via subgroup analyses and sensitivity analyses. Results: Over a median follow-up of 549 days, 123 (2.0%) patients experienced a MACE, and 315 (5.1%) underwent unplanned revascularization. Patients in the MACE group had significantly lower baseline cognitive function. Worse cognitive function was observed in older adults, females, individuals with lower educational attainment, and those with cardiometabolic risk factors. Patients with cognitive impairment had a significantly higher incidence of MACE (log-rank p = 0.001). In contrast, no significant difference was observed in the incidence of unplanned revascularization (log-rank p = 0.791). After multivariable adjustment, cognitive impairment remained an independent predictor of MACE (HR = 1.58, 95% CI: 1.06–2.37, p = 0.026). Sensitivity analyses confirmed the robustness of primary findings. In subgroup analyses, cognitive impairment showed a consistent trend toward increased MACE risk across all strata, with the notable exception of the subgroup with low-density lipoprotein cholesterol < 1.8 mmol/l. Conclusions: Baseline cognitive impairment is an independent predictor of MACE in stable CAD patients.
- Open Access
- 24 April 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
An interpretable machine learning model for predicting stroke in patients with hypertension: insights from the SPRINT
Stroke is a leading cause of mortality worldwide, with hypertension being its most significant risk factor. However, few studies have specifically developed predictive models for stroke risk in hypertensive patients with elevated cardiovascular risk. This study aims to develop and validate an interpretable predictive model based on machine learning (ML) methods to assess stroke risk in hypertensive patients, enabling early prevention and improved prognosis. This study is a secondary analysis of the Systolic Blood Pressure Intervention Trial (SPRINT). Key clinical variables were identified by the least absolute shrinkage and selection operator (LASSO) regression and predictive models were constructed using six machine learning (ML) algorithms. The predictive performance of the models was compared using multiple evaluation metrics, including the area under the receiver operating characteristic curve (AUC), and the results were interpreted using SHapley Additive Explanations (SHAP). A total of 264 participants were selected from the SPRINT dataset using random under-sampling. LASSO regression identified 14 key variables, which were used to develop six ML models. The logistic regression (LR) model was the most effective, with an AUC of 0.810. SHAP analysis indicated that gender, age, systolic blood pressure (SBP), serum creatinine, and race were the most influential factors for stroke risk, with female and higher age, SBP, and serum creatinine levels associated with an increased risk of stroke. An interpretable ML model was developed and validated to predict stroke risk in patients with hypertension and elevated cardiovascular risk, identifying gender, age, and SBP as key contributors. This tool may facilitate individualized risk assessment and support targeted prevention strategies in hypertensive patients at elevated cardiovascular risk.
- 24 April 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Open AccessAn interpretable machine learning model for predicting stroke in patients with hypertension: insights from the SPRINT
Stroke is a leading cause of mortality worldwide, with hypertension being its most significant risk factor. However, few studies have specifically developed predictive models for stroke risk in hypertensive patients with elevated cardiovascular risk. This study aims to develop and validate an interpretable predictive model based on machine learning (ML) methods to assess stroke risk in hypertensive patients, enabling early prevention and improved prognosis. This study is a secondary analysis of the Systolic Blood Pressure Intervention Trial (SPRINT). Key clinical variables were identified by the least absolute shrinkage and selection operator (LASSO) regression and predictive models were constructed using six machine learning (ML) algorithms. The predictive performance of the models was compared using multiple evaluation metrics, including the area under the receiver operating characteristic curve (AUC), and the results were interpreted using SHapley Additive Explanations (SHAP). A total of 264 participants were selected from the SPRINT dataset using random under-sampling. LASSO regression identified 14 key variables, which were used to develop six ML models. The logistic regression (LR) model was the most effective, with an AUC of 0.810. SHAP analysis indicated that gender, age, systolic blood pressure (SBP), serum creatinine, and race were the most influential factors for stroke risk, with female and higher age, SBP, and serum creatinine levels associated with an increased risk of stroke. An interpretable ML model was developed and validated to predict stroke risk in patients with hypertension and elevated cardiovascular risk, identifying gender, age, and SBP as key contributors. This tool may facilitate individualized risk assessment and support targeted prevention strategies in hypertensive patients at elevated cardiovascular risk.
- Open Access
- 10 March 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (6) , 2100
Clinical Benefits of Invasive Strategy in Stable Angina Patients with Low Systolic Blood Pressure: A Post Hoc Analysis of the ISCHEMIA Trial
Background: The ISCHEMIA trial demonstrated no overall prognostic benefit of an initial invasive strategy over optimal medical therapy (OMT) in patients with chronic coronary syndrome (CCS) and moderate-to-severe ischemia. However, managing patients with stable angina and low systolic blood pressure (SBP) remains challenging due to limited tolerance to vasodilatory anti-anginal drugs and the uncertain role of revascularization in improving long-term outcomes for this subgroup. Objectives: This study aimed to estimate the treatment effect of an initial invasive strategy (INV) compared with conservative medical therapy (CON) on long-term clinical outcomes and quality of life in patients with stable angina, particularly those with low baseline systolic blood pressure (≤120 mmHg). Methods: We conducted a post hoc analysis of 3544 patients with stable angina from the ISCHEMIA trial, divided into an initial invasive strategy or a conservative approach. The primary endpoint was a 3-year composite of cardiovascular death, myocardial infarction, hospitalization for unstable angina or heart failure, or resuscitated cardiac arrest. Health-related quality of life was assessed using the Seattle Angina Questionnaire (SAQ). In the subgroup, patients were stratified by baseline SBP, diastolic blood pressure (DBP) and heart rate; the Cox model was adjusted for the covariates. Results: Baseline characteristics were generally comparable between the two groups. Over 3 years of follow-up, no significant difference in primary endpoint events was observed between the INV and CON group in the overall cohort (HR = 0.94, 95%CI 0.77–1.14, p = 0.53), and the INV group had the higher SAQ score. Among patients with low baseline SBP (≤120 mmHg), after adjusting for clinical factors using Cox regression, randomized treatment assignment to the INV approach significantly reduced adverse cardiovascular events compared with conservative therapy (HR = 0.58, 95%CI 0.38 to 0.89). Conclusions: In patients with stable angina, an invasive strategy improved long-term quality of life. Among those with low baseline SBP (≤120 mmHg) and limited tolerance to vasodilatory anti-anginal drugs, invasive management reduced 3-year adverse events, supporting tailored revascularization strategies for these patients; a larger cohort is needed for validation. However, this subgroup-specific causal contrast derives from a post hoc exploratory analysis and should be interpreted cautiously; prospective randomized studies are needed to further validate these findings.
- 10 March 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (6) , 2100
Open AccessClinical Benefits of Invasive Strategy in Stable Angina Patients with Low Systolic Blood Pressure: A Post Hoc Analysis of the ISCHEMIA Trial
Background: The ISCHEMIA trial demonstrated no overall prognostic benefit of an initial invasive strategy over optimal medical therapy (OMT) in patients with chronic coronary syndrome (CCS) and moderate-to-severe ischemia. However, managing patients with stable angina and low systolic blood pressure (SBP) remains challenging due to limited tolerance to vasodilatory anti-anginal drugs and the uncertain role of revascularization in improving long-term outcomes for this subgroup. Objectives: This study aimed to estimate the treatment effect of an initial invasive strategy (INV) compared with conservative medical therapy (CON) on long-term clinical outcomes and quality of life in patients with stable angina, particularly those with low baseline systolic blood pressure (≤120 mmHg). Methods: We conducted a post hoc analysis of 3544 patients with stable angina from the ISCHEMIA trial, divided into an initial invasive strategy or a conservative approach. The primary endpoint was a 3-year composite of cardiovascular death, myocardial infarction, hospitalization for unstable angina or heart failure, or resuscitated cardiac arrest. Health-related quality of life was assessed using the Seattle Angina Questionnaire (SAQ). In the subgroup, patients were stratified by baseline SBP, diastolic blood pressure (DBP) and heart rate; the Cox model was adjusted for the covariates. Results: Baseline characteristics were generally comparable between the two groups. Over 3 years of follow-up, no significant difference in primary endpoint events was observed between the INV and CON group in the overall cohort (HR = 0.94, 95%CI 0.77–1.14, p = 0.53), and the INV group had the higher SAQ score. Among patients with low baseline SBP (≤120 mmHg), after adjusting for clinical factors using Cox regression, randomized treatment assignment to the INV approach significantly reduced adverse cardiovascular events compared with conservative therapy (HR = 0.58, 95%CI 0.38 to 0.89). Conclusions: In patients with stable angina, an invasive strategy improved long-term quality of life. Among those with low baseline SBP (≤120 mmHg) and limited tolerance to vasodilatory anti-anginal drugs, invasive management reduced 3-year adverse events, supporting tailored revascularization strategies for these patients; a larger cohort is needed for validation. However, this subgroup-specific causal contrast derives from a post hoc exploratory analysis and should be interpreted cautiously; prospective randomized studies are needed to further validate these findings.
- Open Access
- 1 September 2025
- Published by Elsevier in Journal of Hazardous Materials
- Vol. 497, 139728
Microplastic contamination in kidney transplant donor tissues and its association with early post-transplant blood pressure changes in recipients: A multi-modal analytical study
- 1 September 2025
- Published by Elsevier in Journal of Hazardous Materials
- Vol. 497, 139728
Open AccessMicroplastic contamination in kidney transplant donor tissues and its association with early post-transplant blood pressure changes in recipients: A multi-modal analytical study
- Open Access
- 1 January 2020
- Published by Wiley in BioMed Research International
- Vol. 2020 (1) , 8137576
Association between Neutrophil Percentage‐to‐Albumin Ratio and All‐Cause Mortality in Critically Ill Patients with Coronary Artery Disease
Background. Neutrophil percentage‐to‐albumin ratio (NPAR) has been proved to be associated with clinical outcome of many diseases. This study was aimed at exploring the independent effect of NPAR on all‐cause mortality of critically ill patients with coronary artery disease (CAD). Method. NPAR was calculated as neutrophil percentage numerator divided by serum albumin concentration. Clinical endpoints were 30‐day, 90‐day, and 365‐day all‐cause mortality. Multivariable Cox proportional hazard models were performed to confirm the association between NPAR and all‐cause mortality. Result. 3106 patients with CAD were enrolled. All‐cause mortality rates of 30 days (P < 0.001), 90 days (P < 0.001), and 365 days (P < 0.001) increased as NPAR tertiles increased. And after adjusting for possible confounding variables, NPAR was still independently associated with 30‐day (third tertile group versus first tertile group: HR, 95% CI: 1.924, 1.471‐2.516; P for trend < 0.001), 90‐day (third tertile group versus first tertile group: HR, 95% CI: 2.053, 1.646‐2.560; P for trend < 0.001), and 365‐day (third tertile group versus first tertile group: HR, 95% CI: 2.063, 1.717‐2.480; P for trend < 0.001) all‐cause mortality in patients with CAD. Subgroup analysis did not find obvious interaction in most subgroups. Conclusion. NPAR was independently correlated with 30‐day, 60‐day, and 365‐day all‐cause mortality in critically ill patients with CAD.
- 1 January 2020
- Published by Wiley in BioMed Research International
- Vol. 2020 (1) , 8137576
Open AccessAssociation between Neutrophil Percentage‐to‐Albumin Ratio and All‐Cause Mortality in Critically Ill Patients with Coronary Artery Disease
Background. Neutrophil percentage‐to‐albumin ratio (NPAR) has been proved to be associated with clinical outcome of many diseases. This study was aimed at exploring the independent effect of NPAR on all‐cause mortality of critically ill patients with coronary artery disease (CAD). Method. NPAR was calculated as neutrophil percentage numerator divided by serum albumin concentration. Clinical endpoints were 30‐day, 90‐day, and 365‐day all‐cause mortality. Multivariable Cox proportional hazard models were performed to confirm the association between NPAR and all‐cause mortality. Result. 3106 patients with CAD were enrolled. All‐cause mortality rates of 30 days (P < 0.001), 90 days (P < 0.001), and 365 days (P < 0.001) increased as NPAR tertiles increased. And after adjusting for possible confounding variables, NPAR was still independently associated with 30‐day (third tertile group versus first tertile group: HR, 95% CI: 1.924, 1.471‐2.516; P for trend < 0.001), 90‐day (third tertile group versus first tertile group: HR, 95% CI: 2.053, 1.646‐2.560; P for trend < 0.001), and 365‐day (third tertile group versus first tertile group: HR, 95% CI: 2.063, 1.717‐2.480; P for trend < 0.001) all‐cause mortality in patients with CAD. Subgroup analysis did not find obvious interaction in most subgroups. Conclusion. NPAR was independently correlated with 30‐day, 60‐day, and 365‐day all‐cause mortality in critically ill patients with CAD.
- Open Access
- 1 January 2020
- Published by Wiley in BioMed Research International
- Vol. 2020 (1) , 4598462
Anion Gap Was Associated with Inhospital Mortality and Adverse Clinical Outcomes of Coronary Care Unit Patients
Background. Anion gap (AG) has been proved to be associated with prognosis of many cardiovascular diseases. This study is aimed at exploring the association of AG with inhospital all‐cause mortality and adverse clinical outcomes in coronary care unit (CCU) patients. Method. All data of this study was extracted from Medical Information Mart for Intensive Care III (MIMIC‐III, version 1.4) database. All patients were divided into four groups according to AG quartiles. Primary outcome was inhospital all‐cause mortality. Lowess smoothing curve was drawn to describe the overall trend of inhospital mortality. Binary logistic regression analysis was performed to determine the independent effect of AG on inhospital mortality. Result. A total of 3593 patients were enrolled in this study. In unadjusted model, as AG quartiles increased, inhospital mortality increased significantly, OR increased stepwise from quartile 2 (OR, 95% CI: 1.01, 0.74‐1.38, P = 0.958) to quartile 4 (OR, 95% CI: 2.72, 2.08‐3.55, P < 0.001). After adjusting for possible confounding variables, this association was attenuated, but still remained statistically significant (quartile 1 vs. quartile 4: OR, 95% CI: 1.02, 0.72‐1.45 vs. 1.49, 1.07‐2.09, P = 0.019). Moreover, CCU mortality (P < 0.001) and rate of acute kidney injury (P < 0.001) were proved to be higher in the highest AG quartiles. Length of CCU (P < 0.001) and hospital stay (P < 0.001) prolonged significantly in higher AG quartiles. Maximum sequential organ failure assessment score (SOFA) (P < 0.001) and simplified acute physiology score II (SAPSII) (P < 0.001) increased significantly as AG quartiles increased. Moderate predictive ability of AG on inhospital (AUC: 0.6291), CCU mortality (AUC: 0.6355), and acute kidney injury (AUC: 0.6096) was confirmed. The interactions were proved to be significant in hypercholesterolemia, congestive heart failure, chronic lung disease, respiratory failure, oral anticoagulants, Beta‐blocks, angiotensin‐converting enzyme inhibitor (ACEI)/angiotensin receptor blocker (ARB), and vasopressin treatment subgroups. Conclusion. AG was an independent risk factor of inhospital all‐cause mortality and was associated with adverse clinical outcomes in CCU patients.
- 1 January 2020
- Published by Wiley in BioMed Research International
- Vol. 2020 (1) , 4598462
Open AccessAnion Gap Was Associated with Inhospital Mortality and Adverse Clinical Outcomes of Coronary Care Unit Patients
Background. Anion gap (AG) has been proved to be associated with prognosis of many cardiovascular diseases. This study is aimed at exploring the association of AG with inhospital all‐cause mortality and adverse clinical outcomes in coronary care unit (CCU) patients. Method. All data of this study was extracted from Medical Information Mart for Intensive Care III (MIMIC‐III, version 1.4) database. All patients were divided into four groups according to AG quartiles. Primary outcome was inhospital all‐cause mortality. Lowess smoothing curve was drawn to describe the overall trend of inhospital mortality. Binary logistic regression analysis was performed to determine the independent effect of AG on inhospital mortality. Result. A total of 3593 patients were enrolled in this study. In unadjusted model, as AG quartiles increased, inhospital mortality increased significantly, OR increased stepwise from quartile 2 (OR, 95% CI: 1.01, 0.74‐1.38, P = 0.958) to quartile 4 (OR, 95% CI: 2.72, 2.08‐3.55, P < 0.001). After adjusting for possible confounding variables, this association was attenuated, but still remained statistically significant (quartile 1 vs. quartile 4: OR, 95% CI: 1.02, 0.72‐1.45 vs. 1.49, 1.07‐2.09, P = 0.019). Moreover, CCU mortality (P < 0.001) and rate of acute kidney injury (P < 0.001) were proved to be higher in the highest AG quartiles. Length of CCU (P < 0.001) and hospital stay (P < 0.001) prolonged significantly in higher AG quartiles. Maximum sequential organ failure assessment score (SOFA) (P < 0.001) and simplified acute physiology score II (SAPSII) (P < 0.001) increased significantly as AG quartiles increased. Moderate predictive ability of AG on inhospital (AUC: 0.6291), CCU mortality (AUC: 0.6355), and acute kidney injury (AUC: 0.6096) was confirmed. The interactions were proved to be significant in hypercholesterolemia, congestive heart failure, chronic lung disease, respiratory failure, oral anticoagulants, Beta‐blocks, angiotensin‐converting enzyme inhibitor (ACEI)/angiotensin receptor blocker (ARB), and vasopressin treatment subgroups. Conclusion. AG was an independent risk factor of inhospital all‐cause mortality and was associated with adverse clinical outcomes in CCU patients.